Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Disclosing ties among drugmakers, doctors

by Britt E. Erickson
February 2, 2009 | A version of this story appeared in Volume 87, Issue 5

In a continued effort to disclose financial relationships between drugmakers and doctors, Sens. Chuck Grassley (R-Iowa) and Herb Kohl (D-Wis.) have introduced legislation that would require pharmaceutical, medical device, and biologics manufacturers to report all money over $100 they give to physicians. The Physician Payments Sunshine Act of 2009 would establish a national standard under which drug and device manufacturers supply information to the Department of Health & Human Services about payments they make to doctors. Record of the payments also would have to be posted on the Internet in a publicly accessible way. The bill would establish a penalty of up to $1 million for companies that do not disclose such information. Grassley's ongoing investigation has revealed large amounts of undisclosed money going to prominent research doctors. He recently pressured NIH to require disclosure of financial relationships between drug manufacturers and doctors who conduct federally funded medical research.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.